Journey Medical (DERM) EBIT: 2020-2025
Historic EBIT for Journey Medical (DERM) over the last 5 years, with Sep 2025 value amounting to -$1.5 million.
- Journey Medical's EBIT rose 47.17% to -$1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.5 million, marking a year-over-year increase of 69.50%. This contributed to the annual value of -$13.7 million for FY2024, which is 559.77% down from last year.
- According to the latest figures from Q3 2025, Journey Medical's EBIT is -$1.5 million, which was up 46.84% from -$2.9 million recorded in Q2 2025.
- In the past 5 years, Journey Medical's EBIT registered a high of $17.2 million during Q3 2023, and its lowest value of -$13.8 million during Q2 2021.
- Over the past 3 years, Journey Medical's median EBIT value was -$2.9 million (recorded in 2024), while the average stood at -$2.1 million.
- Per our database at Business Quant, Journey Medical's EBIT tumbled by 5,391.21% in 2021 and then soared by 281.68% in 2023.
- Over the past 5 years, Journey Medical's EBIT (Quarterly) stood at -$9.1 million in 2021, then decreased by 10.36% to -$10.0 million in 2022, then skyrocketed by 78.95% to -$2.1 million in 2023, then skyrocketed by 206.18% to $2.2 million in 2024, then skyrocketed by 47.17% to -$1.5 million in 2025.
- Its EBIT was -$1.5 million in Q3 2025, compared to -$2.9 million in Q2 2025 and -$3.3 million in Q1 2025.